C. Mitchell

Survival in children with perinatally acquired human immunodeficiency virus type 1 infection

R. Makuch, E. Trapido, W. Parks, 1989 .

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

R. Nelson, J. Church, J. Sleasman, 2001, Pediatrics.

Survival in children with perinatally acquired human immunodeficiency virus type 1 infection

T. O'connor, W. Parks, C. Hutto, 1990, The New England journal of medicine.

Survival in children with perinatally acquired human immunodeficiency virus type 1 infection.

W. Parks, C. Hutto, R. Makuch, 1989 .

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082)

W. Parks, S. Weller, Y. Bryson, 1993 .

Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group.

R. Gelber, W. Borkowsky, M. Fowler, 1996, The Journal of infectious diseases.

A hospital-based prospective study of perinatal infection with human immunodeficiency virus type 1.

W. Parks, G. Scott, J. Muñoz, 1991, The Journal of pediatrics.

Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1.

M. Cowles, D. H. Watts, L. Frenkel, 1997, The Journal of infectious diseases.